ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis
Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the...
Gespeichert in:
| Veröffentlicht in: | Journal of thrombosis and thrombolysis 2012-07, Vol.34 (1), p.73-78 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 78 |
|---|---|
| container_issue | 1 |
| container_start_page | 73 |
| container_title | Journal of thrombosis and thrombolysis |
| container_volume | 34 |
| creator | Rios, Danyelle R. A. Carvalho, Maria G. Figueiredo, Roberta C. Ferreira, Cláudia N. Rodrigues, Valério L. Souza, Regina A. Silva, Ana C. Simões e Fernandes, Ana Paula Gomes, Karina B. Dusse, Luci M. S. |
| description | Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the association between these markers and VAT occurrence. This study included 195 patients on HD for more than 6 months. HD patients were allocated into two groups according to the occurrence or not of previous episode of VAT; HD with VAT (
N
= 46) and HD without VAT (
N
= 149). ADAMTS13 and VWF were performed by ELISA. There was no significant difference between HD patients with and without VAT for ADAMTS13 and VWF levels. However, VWF levels were higher (
P
|
| doi_str_mv | 10.1007/s11239-012-0682-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1034514571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1034514571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-54c8738ded23b6e3e7c566f3d7af8d642c1ff20224935b3d74a0b553d12c4e7e3</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EouXjB7CgSCwsBvtsx8lYFQpIRQyUjy1yYqekSp1iJ0P_PY5SEEJiss733HunB6EzSq4oIfLaUwosxYQCJnECmO6hMRWSYcnhfR-NSQopFoyIETryfkUISVMCh2gEAGkCnI_RbHIzeVw8UxYpq6PXxkZvVV2b3PVlqYq2cVFlo41qK2NbH3VWG7dsKruMPsy60ZWqt77yJ-igVLU3p7v3GL3MbhfTezx_unuYTua4YBJaLHiRSJZoo4HlsWFGFiKOS6alKhMdcyhoWQIB4CkTefjmiuRCME2h4EYadowuh9yNaz4749tsXfnC1LWypul8RgnjgnIhaUAv_qCrpnM2XBcooAxEksSBogNVuMZ7Z8ps46q1ctsAZb3kbJCcBclZLznrk893yV2-Nvpn4ttqAGAAfGjZpXG_V_-X-gUbrYUT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1021325886</pqid></control><display><type>article</type><title>ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rios, Danyelle R. A. ; Carvalho, Maria G. ; Figueiredo, Roberta C. ; Ferreira, Cláudia N. ; Rodrigues, Valério L. ; Souza, Regina A. ; Silva, Ana C. Simões e ; Fernandes, Ana Paula ; Gomes, Karina B. ; Dusse, Luci M. S.</creator><creatorcontrib>Rios, Danyelle R. A. ; Carvalho, Maria G. ; Figueiredo, Roberta C. ; Ferreira, Cláudia N. ; Rodrigues, Valério L. ; Souza, Regina A. ; Silva, Ana C. Simões e ; Fernandes, Ana Paula ; Gomes, Karina B. ; Dusse, Luci M. S.</creatorcontrib><description>Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the association between these markers and VAT occurrence. This study included 195 patients on HD for more than 6 months. HD patients were allocated into two groups according to the occurrence or not of previous episode of VAT; HD with VAT (
N
= 46) and HD without VAT (
N
= 149). ADAMTS13 and VWF were performed by ELISA. There was no significant difference between HD patients with and without VAT for ADAMTS13 and VWF levels. However, VWF levels were higher (
P
< 0.001) and ADAMTS13 were lower (
P
< 0.001) in HD patients, comparing to the control group composed by healthy subjects without kidney disease, age and sex-matched (
N
= 80). Taken together our data suggest a potential role of the kidneys function compromised on ADAMTS13 synthesis or metabolism, regardless other known sources of ADAMTS13. The imbalance between ADAMTS13 and VWF levels does not explain the development of VAT in HD patients by itself, although it should contribute for the hypercoagulability state. Therefore, additional studies to identify other risk factors are warranted and essential for better management of HD patients.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-012-0682-1</identifier><identifier>PMID: 22298244</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>ADAM Proteins - blood ; ADAMTS13 Protein ; Adolescent ; Adult ; Aged ; Biomarkers - blood ; Cardiology ; Enzyme-Linked Immunosorbent Assay ; Female ; Hematology ; Humans ; Kidney - metabolism ; Kidney Diseases - blood ; Kidney Diseases - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Renal Dialysis - adverse effects ; Thrombosis - blood ; Thrombosis - etiology ; Time Factors ; von Willebrand Factor - metabolism</subject><ispartof>Journal of thrombosis and thrombolysis, 2012-07, Vol.34 (1), p.73-78</ispartof><rights>Springer Science+Business Media, LLC 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-54c8738ded23b6e3e7c566f3d7af8d642c1ff20224935b3d74a0b553d12c4e7e3</citedby><cites>FETCH-LOGICAL-c372t-54c8738ded23b6e3e7c566f3d7af8d642c1ff20224935b3d74a0b553d12c4e7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11239-012-0682-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11239-012-0682-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22298244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rios, Danyelle R. A.</creatorcontrib><creatorcontrib>Carvalho, Maria G.</creatorcontrib><creatorcontrib>Figueiredo, Roberta C.</creatorcontrib><creatorcontrib>Ferreira, Cláudia N.</creatorcontrib><creatorcontrib>Rodrigues, Valério L.</creatorcontrib><creatorcontrib>Souza, Regina A.</creatorcontrib><creatorcontrib>Silva, Ana C. Simões e</creatorcontrib><creatorcontrib>Fernandes, Ana Paula</creatorcontrib><creatorcontrib>Gomes, Karina B.</creatorcontrib><creatorcontrib>Dusse, Luci M. S.</creatorcontrib><title>ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the association between these markers and VAT occurrence. This study included 195 patients on HD for more than 6 months. HD patients were allocated into two groups according to the occurrence or not of previous episode of VAT; HD with VAT (
N
= 46) and HD without VAT (
N
= 149). ADAMTS13 and VWF were performed by ELISA. There was no significant difference between HD patients with and without VAT for ADAMTS13 and VWF levels. However, VWF levels were higher (
P
< 0.001) and ADAMTS13 were lower (
P
< 0.001) in HD patients, comparing to the control group composed by healthy subjects without kidney disease, age and sex-matched (
N
= 80). Taken together our data suggest a potential role of the kidneys function compromised on ADAMTS13 synthesis or metabolism, regardless other known sources of ADAMTS13. The imbalance between ADAMTS13 and VWF levels does not explain the development of VAT in HD patients by itself, although it should contribute for the hypercoagulability state. Therefore, additional studies to identify other risk factors are warranted and essential for better management of HD patients.</description><subject>ADAM Proteins - blood</subject><subject>ADAMTS13 Protein</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Cardiology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Kidney - metabolism</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Renal Dialysis - adverse effects</subject><subject>Thrombosis - blood</subject><subject>Thrombosis - etiology</subject><subject>Time Factors</subject><subject>von Willebrand Factor - metabolism</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kD1PwzAQhi0EouXjB7CgSCwsBvtsx8lYFQpIRQyUjy1yYqekSp1iJ0P_PY5SEEJiss733HunB6EzSq4oIfLaUwosxYQCJnECmO6hMRWSYcnhfR-NSQopFoyIETryfkUISVMCh2gEAGkCnI_RbHIzeVw8UxYpq6PXxkZvVV2b3PVlqYq2cVFlo41qK2NbH3VWG7dsKruMPsy60ZWqt77yJ-igVLU3p7v3GL3MbhfTezx_unuYTua4YBJaLHiRSJZoo4HlsWFGFiKOS6alKhMdcyhoWQIB4CkTefjmiuRCME2h4EYadowuh9yNaz4749tsXfnC1LWypul8RgnjgnIhaUAv_qCrpnM2XBcooAxEksSBogNVuMZ7Z8ps46q1ctsAZb3kbJCcBclZLznrk893yV2-Nvpn4ttqAGAAfGjZpXG_V_-X-gUbrYUT</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Rios, Danyelle R. A.</creator><creator>Carvalho, Maria G.</creator><creator>Figueiredo, Roberta C.</creator><creator>Ferreira, Cláudia N.</creator><creator>Rodrigues, Valério L.</creator><creator>Souza, Regina A.</creator><creator>Silva, Ana C. Simões e</creator><creator>Fernandes, Ana Paula</creator><creator>Gomes, Karina B.</creator><creator>Dusse, Luci M. S.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis</title><author>Rios, Danyelle R. A. ; Carvalho, Maria G. ; Figueiredo, Roberta C. ; Ferreira, Cláudia N. ; Rodrigues, Valério L. ; Souza, Regina A. ; Silva, Ana C. Simões e ; Fernandes, Ana Paula ; Gomes, Karina B. ; Dusse, Luci M. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-54c8738ded23b6e3e7c566f3d7af8d642c1ff20224935b3d74a0b553d12c4e7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>ADAM Proteins - blood</topic><topic>ADAMTS13 Protein</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Cardiology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Kidney - metabolism</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Renal Dialysis - adverse effects</topic><topic>Thrombosis - blood</topic><topic>Thrombosis - etiology</topic><topic>Time Factors</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rios, Danyelle R. A.</creatorcontrib><creatorcontrib>Carvalho, Maria G.</creatorcontrib><creatorcontrib>Figueiredo, Roberta C.</creatorcontrib><creatorcontrib>Ferreira, Cláudia N.</creatorcontrib><creatorcontrib>Rodrigues, Valério L.</creatorcontrib><creatorcontrib>Souza, Regina A.</creatorcontrib><creatorcontrib>Silva, Ana C. Simões e</creatorcontrib><creatorcontrib>Fernandes, Ana Paula</creatorcontrib><creatorcontrib>Gomes, Karina B.</creatorcontrib><creatorcontrib>Dusse, Luci M. S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rios, Danyelle R. A.</au><au>Carvalho, Maria G.</au><au>Figueiredo, Roberta C.</au><au>Ferreira, Cláudia N.</au><au>Rodrigues, Valério L.</au><au>Souza, Regina A.</au><au>Silva, Ana C. Simões e</au><au>Fernandes, Ana Paula</au><au>Gomes, Karina B.</au><au>Dusse, Luci M. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>34</volume><issue>1</issue><spage>73</spage><epage>78</epage><pages>73-78</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>Hemodialysis (HD) is associated with increasing thrombotic trend. Vascular access thrombosis (VAT) increases morbidity in HD patients. The aim of this study was to evaluate ADAMTS13 and VWF plasma levels from patients undergoing HD as putative biomarkers of the hypercoagulability state, as well the association between these markers and VAT occurrence. This study included 195 patients on HD for more than 6 months. HD patients were allocated into two groups according to the occurrence or not of previous episode of VAT; HD with VAT (
N
= 46) and HD without VAT (
N
= 149). ADAMTS13 and VWF were performed by ELISA. There was no significant difference between HD patients with and without VAT for ADAMTS13 and VWF levels. However, VWF levels were higher (
P
< 0.001) and ADAMTS13 were lower (
P
< 0.001) in HD patients, comparing to the control group composed by healthy subjects without kidney disease, age and sex-matched (
N
= 80). Taken together our data suggest a potential role of the kidneys function compromised on ADAMTS13 synthesis or metabolism, regardless other known sources of ADAMTS13. The imbalance between ADAMTS13 and VWF levels does not explain the development of VAT in HD patients by itself, although it should contribute for the hypercoagulability state. Therefore, additional studies to identify other risk factors are warranted and essential for better management of HD patients.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>22298244</pmid><doi>10.1007/s11239-012-0682-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-5305 |
| ispartof | Journal of thrombosis and thrombolysis, 2012-07, Vol.34 (1), p.73-78 |
| issn | 0929-5305 1573-742X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1034514571 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | ADAM Proteins - blood ADAMTS13 Protein Adolescent Adult Aged Biomarkers - blood Cardiology Enzyme-Linked Immunosorbent Assay Female Hematology Humans Kidney - metabolism Kidney Diseases - blood Kidney Diseases - therapy Male Medicine Medicine & Public Health Middle Aged Renal Dialysis - adverse effects Thrombosis - blood Thrombosis - etiology Time Factors von Willebrand Factor - metabolism |
| title | ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A19%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ADAMTS13%20and%20Von%20Willebrand%20factor%20in%20patients%20undergoing%20hemodialysis&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Rios,%20Danyelle%20R.%20A.&rft.date=2012-07-01&rft.volume=34&rft.issue=1&rft.spage=73&rft.epage=78&rft.pages=73-78&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-012-0682-1&rft_dat=%3Cproquest_cross%3E1034514571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1021325886&rft_id=info:pmid/22298244&rfr_iscdi=true |